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In this study, we fabricated porous PLGA microparticles loaded with EGCG by a modified water-in-oil-in-water (W/
O/W) double emulsion solvent evaporation method. The physicochemical properties of the EGCG-loaded PLGA
microparticles were studied using scanning electron microscopy (SEM), Fourier transformed-infrared (FT-IR) spectros-
copy and in vitro release measurements. A remarkable burst effect was observed on first stage however the released
amount was reduced largely with time. This result showed that the release of EGCG increased by its loading
amount. Also, EGCG - loaded PLGA particles inhibited the growth of rat aortic smooth muslce cells (RASMC). This
study demonstrates that PLGA microparticle system is potential as an efficient EGCG carrier in medical therapy.
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Introduction
everal epidemiological studies have suggested that green
tea has pharmacological effects associated with a reduced
risk of degenerative disease such as cancer and cardiovascular
disease. Among the green tea polyphenols, epigallocatechin-3-
gallate (EGCG) is the major component of green tea that
mediates cardiovascular-related effects such as anti-prolifera-
tive,1,2) anti-atherogenic3) and anti-thrombotic.4) Furthermore,
recent studies have demonstrated that EGCG has ability of
preventing angioplasty-induced restenosis, suppressing vascular
smooth muscle cells (SMCs) proliferation and migration4,5) and
inhibiting the activities of some matrix metalloproteinases
(MMPs).6) On these bases, it can be assumed that EGCG has
a protective effect on the vascular dysfunction and intimal
hyperplasia after vascular damage. Local delivery of water-sol-
uble EGCG may be needed for a successful vascularization
from injured vessels.
For the purpose of a sustained drug release, a drug delivery
system using biodegradable polymer microparticles has been
focused with its potentials.7,8) PLGA has been often used for
drug delivery systems because of its proven safety and efficacy
in sustained release. Drugs may be incorporated into PLGA
microparticles by a variety of techniques including encapsula-
tion method. Among the encapsulation techniques, the o/o
solvent evaporation9) and the w/o/w solvent extraction
techniques10-12) are two of the most convenient ways for the
encapsulation of drug within PLGA microparticles. According
to the used encapsulation methods, PLGA molecular weight,
and stabilizers the drug encapsulation efficiency, diffusion of
drug, morphological features of the PLGA microparticles and
burst release can be determined.
In this study, the EGCG-loaded microparticles were pre-
pared by a double emulsion solvent technique using a biode-
gradable copolymer of poly (lactic-co-glycolic acid) (PLGA)
and in vitro EGCG release study from PLGA microparticles
was performed. 
Materials and Methods
Materials
PLGA (50:50) polymer (Mw 72.3 kDa) was purchased from
Lakeshore Biomaterials, Inc (AL, USA). EGCG (MW 458.4)
was supplied by TeavigoTM (DSM Nutritional Products Ltd.,
Basel, Switzerland) and its purity exceeded 93%. Dichlo-
romethane (DCM), polyvinyl alcohol (PVA), DMSO and iso-
propyl alcohol were purchased from Sigma-Aldrich Co., (St.
Louis., USA).
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Preparation of PLGA microparticles 
EGCG-loaded PLGA microparticles were produced by mod-
ification of a water-in-oil-in-water double emulsion, solvent
extraction technique. Briefly, 600 mg PLGA was dissolved in
5 mL of DCM and 0, 15, 30, 60 mg of EGCG were dissolved
into 1 mL of distilled water, respectively. After mixing these
two solutions vigorously for 10min by a vortex mixer, emulsi-
fied solution was re-emulsified in 50 mL of PVA (0.2%, w/v).,
Solution was poured in 50 mL of aqueous isopropyl alcohol
(2%, w/v) and stirred with a magnetic stirrer for overnight at
room temperature to harden fabricated microparticles. Also,
EGCG-free microparticles were prepared accordingly without
EGCG. Fabricated PLGA microparticles were rinsed three
times with pH 7.4 phosphate buffered saline (PBS) to remove
the un-captured EGCG and lyophilized in a freeze-dryer.
Dried microparticles were stored in -20 oC.
Characterization of PLGA microparticles 
Determination of EGCG loading amount and efficiency
To determine EGCG amount loaded in the PLGA micropar-
ticles, 10 mg of microparticles were dissolved in 5 mL DMSO
and analyzed at 312 nm by UV-Vis spectrophotometer. The
concentration of EGCG released from particle was calculated
from the standard calibration curve of EGCG solution. The
relationship between the input amount of EGCG and the
EGCG loading content of particle was investigated:
The yield of the produced microparticles and EGCG loading
efficiency were calculated as followings;
Yield = Weight of EGCG-loaded PLGA in production/ 
Total weights of input EGCG and input PLGA × 100
(1)
EGCG loading efficiency = Actual loading amount of EGCG/
Input amount of EGCG × 100
(2)
PLGA microparticles morphology
Prepared PLGA microparticles were coated by gold and
their surfaces and sizes were observed by a scanning elec-
tronic microscope (Hitachi S-800, Tokyo, Japan). The micro-
particles were mounted and sputter-coated with gold/platinum
using an ion coater (E1010, Hitachi) and then observed at an
accelerating voltage of 20 kV.
Fourier transformed-infrared (FT-IR) spectroscopy 
Fourier transform infrared (FT-IR) spectra of EGCG, PLGA
and EGCG- PLGA particle were obtained between 4000 and
650 cm-1 using an FT-IR spectrophotometer (NicoletTM 380,
Thermo Fisher Scientific, Inc., Waltham, MA). Samples were
scanned 128 times at 8 cm-1 resolution.
In vitro release of EGCG from particle
The 50 mg of EGCG-loaded PLGA microparticles were sus-
pended in 5 mL of PBS (pH 7.4) and incubated at 37 oC with
shaking at 224 rpm. Aliquots of supernatant were replaced
with an equal amount of fresh PBS to maintain a constant vol-
ume of buffer at predetermined time intervals. The suspended
solution was centrifuged at 25 oC and 1600 rpm for 10 min.
The concentrations of EGCG from released buffer were deter-
mined at 280 nm by UV-Vis spectrophotometer from the stan-
dard calibration curve of EGCG solution. The accumulated
release percentage of EGCG at each time point was detected
from three replicate samples for 23 days.
Cell culture and growth inhibition assay of EGCG-PLGA
particle
RASMCs (Rat Aortic smooth muscle cells) were purchased
from BioBud (Seoul, Korea) and used between passages 7 and
15. The cells were routinely maintained in Dulbecco’s modi-
fied Eagle’s medium (Wellgene, Seoul, Korea) supplemented
with 10% FBS (HyClone Laboratories Inc, UT, USA) and a 1%
antibiotic antimycotic solution (including 10,000 U penicillin,
10 mg streptomycin, and 25 µg amphotericin B per ml,
Wellgene) at 37 oC in a humidified atmosphere of 5% CO2 in air.
In order to examine the growth inhibitory effects of EGCG-
loaded PLGA microparticles on RASMCs, the cells were
seeded into 48well plates and incubated for 4hr at 37 oC in a
humidified atmosphere of 5% CO2 in air. After the cells were
attached, they were treated with EGCG-loaded PLGA particles
(20 mg/ml) and incubated for 1d, 3d, and 5d, respectively.
EGCG-loaded PLGA particles were sterilized by low tempera-
ture EO gas (3M™ Steri-Vac™ 5XL Gas Sterilizer/Aerators, 3M,
St. Paul, MN) before the treatment to RASMC. Cell viability
was determined by MTT assay [reduction of 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide to a purple forma-
zan product].
Results and discussions 
Preparation of biodegradable microparticles containing
water-soluble bioactive agents has received much attention in
recent years, due to their numerous advantages compared to
conventional dosage forms, which include improved efficacy,
reduced toxicity, and improved patient compliance and con-
venience. Various techniques are available to entrap water sol-
uble bioactive agents into biodegradable microparticles.
Among various methods, the W/O/W double emulsion tech-
nique is the most popular method.13)
EGCG-loaded PLGA microparticles were prepared by the
W1/O/W2 emulsification-solvent evaporation method. The
morphology of PLGA microparticles was observed by SEM
(Figure 1). Although the size of microparticles was diverse, the
average size was from 100 µm to 300 µm. Moreover, the
PLGA microparticle were spherical with several pores distrib-
uted on their surface, irrespective of their dimension (Figure 1
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A, B, C, D). However, the pore number decreased with
increasing EGCG concentration (Figure 1 E, F, G, H). Porosity
of microparticles is known to vary with numerous factors such
as polymer molecular mass, co-solvent concentration, dis-
persed phase to continuous phase ratio, drug concentration,
rate and method of solvent removal.15) Pores are formed
because of the inner aqueous phase during microparticle for-
mation in the water-in-oil-in-water (W/O/W) method, in com-
parsion with the oil-in-water method. In the organic phase,
the polymer concentration continuously increases during
organic solvent extraction/evaporation. The PLGA begins to
precipitate and encapsulate the drug as well as inner water
droplets. By elimination of the water during drying, empty
holes remain and are uniformly distributed throughout the
microparticles, irrespective of their size.14) 
However, once the microparticles are dried, in EGCG-
loaded particles the empty holes are filled by EGCG that was
included in water. We observed that the inside of pore is filled
with loaded-EGCG compared with non-treated microparticles
(Figure 1 E, F, G, H). Moreover, it has been observed that the
size of pores decreased with the increasing EGCG concentra-
tion in EGCG-loaded microparticles.
The actual load of EGCG in PLGA microparticles was calcu-
lated by spectrophotometric analysis. The actual loading
amount and efficiency of EGCG are presented Table 1. The
production yield of PLGA microparticles gradually was
decreased by addition of EGCG. The actual EGCG loading
was almost identical in all cases. The EGCG loading efficien-
cies were found to be 8~13 % with no significant difference
with increasing EGCG concentration. Although the loading
efficiency has been reported to be related to surfactant con-
centration and viscosity in oil phase, stirring time period and
stirring rate in the preparation procedure of primary emulsion,
stirring rate in secondary emulsion preparation, polymer con-
centration, and osmotic pressure, drug loading efficiency and
particle size of microparticle can not be completely con-
trolled.15,16)
The FT-IR spectra of the representative formulations con-
firmed that the EGCG was dissolved in the microparticle (Figure
2). FT-IR spectra of EGCG-loaded particles were dominated by
Figure 1. Scanning electron micrographs images (SEM) of PLGA microparticles. (A, E) 0 mg ; (B, F) 15 mg ; (C, G) 30 mg ; (D, H)
60 mg of EGCG was loaded microparticles. Upper panel: 200 magnification, down panel: 1.0 K magnification.
Table 1. Encapsulation efficiency and burst effect of EGCG-loaded PLGA microparticles.
EGCG(mg)/PLGA(mg) Yield
Theoretical loaded 
EGCG (mg)
Actual loaded-EGCG (mg) EGCG loading efficiency (%)
0/600 94.58±1.58 - - -
15/600 90.09±0.98 15 1.59±0.39 10.61±2.58
30/600 84.21±0.34 30 3.11±0.53 10.36±1.78
60/600 76.67±0.37 600 5.50±0.63 9.17±1.04
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a broad notable band at phenyl-OH group (3600–3150 cm-1),
which is the characteristic peak of EGCG. Therefore, the char-
acteristic phenyl-OH peak was stretched with increasing
EGCG concentration. The change in this peak was similar with
EGCG releasing PLCL film prepared by solvent casting.17) It
seems that EGCG was encapsulated in the PLGA microparticle,
probably by dispersion of EGCG in polymer.
The release experiments in vitro were carried out by spec-
trophotometrical method for 23 days. The EGCG release pro-
files from the PLGA microparticles in PBS are illustrated in
Figure 3 for different concentration of EGCG. The EGCG
release profiles were biphasic, remarkable burst effect was
observed on the first and second day. However, the released
concentration of EGCG was largely reduced from the third
day and kept constant for 3 weeks. The highest burst effect
and release rate was observed in microparticles with the high-
est concentration of EGCG. Burst release from PLGA micro-
particles has been attributed to either the surface or uniform
distribution of the associated drug. Therefore, to reach the
sustained release the drug should be distributed exclusively
inside the microparticle. Porosity increases the surface area of
the microparticle, which itself can contribute to the burst.18) A
successful microparticle should yield high encapsulation effi-
ciency, and desired particle size. 
Other studies have already shown that EGCG has pharma-
cological activites, including antioxidant, anti-proliferative, anti-
thrombotic and anti-migrative effect on smooth muscle
cells.1,4,19) In this study, we examined the growth inhibitory
effect on RASMC by EGCG-loaded PLGA microparticles (Fig-
ure 4). When the cells were treated with EGCG-loaded micro-
particles, cell proliferation significantly decreased with increas-
ing EGCG concentration dose dependently in comparison
with the unloaded PLGA microparticles. Our previous results
had shown that proliferation and migration in serum-stimu-
lated RASMC was inhibited in more than 200 µM EGCG.5) By
calculation, PLGA microparticles manufactured by different
concentration of EGCG (15:600, 30:600 and 60:600) loaded
1.5 mg, 30 mg and 60 mg, respectively. Our results showed
that RASMC proliferation was inhibited by EGCG released
from PLGA microparticles for the first 5 days.
Microparticles should provide effective and sustainable
release to control the drug release kinetics over periods of
days to months. Thus, PLGA microparticles for local delivery
of EGCG can be very helpful to optimize the therapeutic effi-
ciency and to reduce possible side effects in medical applica-
tion of EGCG.
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Figure 2. FT-IR spectrums of EGCG-loaded PLGA microparti-
cles.
Figure 3. In vitro release behavior of EGCG from PLGA microparticles.
Released EGCG was observed at 280 nm with control for 23 days (PBS
buffer, pH 7.4, 37 oC).
Figure 4. Effect of EGCG-loaded PLGA microparticles on
RASMC proliferation. The results are reported as means ± SD
(n = 4). The data are analyzed by a t-test. The values marked
with asterisks are significantly different from the unloaded
PLGA microparticle (0:600) (*p < 0.05). 
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